Meanwhile, the unique down-regulated gene in the group of TP53 mutation in LCC, FOXA1, which has been reported to inhibit T cells proliferation in lung cancer (49), was also observed to be down-regulated in the high-immunity group of LCC (Figure 8F), indicating that TP53 mutation may exhibit a suppressive function against immunity inhibition in LCC. The gene discussed is FOXA1; the disease is leukoencephalopathy with calcifications and cysts.